Search Results
Your search for ,maY matches 16983 pages
Showing 16001 - 16050Study Shows That Previous Cancer ‘False Alarms’ May Discourage Patients From Screening Future Symptoms
Cancer researchers at University College London (UCL) have found that a cancer false alarm could discourage patients from checking out cancer symptoms they develop in the future. More than 80% of patients with potential cancer symptoms are given the all-clear after investigations. But according to ...
FDA Analysis Explores Relationship Between Response Rate and Survival at Trial and Patient Levels in Advanced NSCLC Studies
In a U.S. Food and Drug Administration (FDA) analysis of randomized trials in advanced non–small cell lung cancer (NSCLC) reported in the Journal of Clinical Oncology, Blumenthal et al found a strong correlation between response rate and progression-free survival at the trial level and a...
Survivors of Childhood Cancer at Risk for Developing Hormone Deficiencies as Adults
Decades after undergoing cranial irradiation for childhood cancer, St. Jude Children's Research Hospital investigators found that adult survivors of pediatric cancer remain at risk for pituitary hormone deficiencies, which may diminish their health and quality of life. Chemaitilly et al published...
12-Year Study Suggests Procedures to Prevent Cervical Cancer Do Not Affect Fertility
Common surgical procedures used to diagnose and treat precancerous cervical lesions do not decrease women's chances of becoming pregnant, according to a study conducted by Kaiser Permanente Northwest, which followed nearly 100,000 women for up to 12 years. In fact, researchers found that women ...
Early Study Suggests Olaparib May Be Effective in Ovarian Cancers Expressing High Levels of POLQ
Last December, the U.S. Food and Drug Administration (FDA) approved olaparib (Lynparza) in the treatment of advanced ovarian cancer in women with BRCA1 or BRCA2 gene mutations. Now, a laboratory study by Ceccaldi et al has found that the drug may also be effective in breast and ovarian tumors that...
Higher Folate Intake Associated With Reduced Risk of Hormone Receptor–Negative Breast Cancer in Premenopausal Women
In an analysis from the European Prospective Investigation Into Cancer and Nutrition (EPIC) reported in the Journal of the National Cancer Institute, de Batlle and colleagues found reduced risks of estrogen receptor–negative and progesterone receptor–negative breast cancer for highest...
TP53 Mutations Common in Pediatric Adrenocortical Carcinoma
In a Children’s Oncology Group study reported in the Journal of Clinical Oncology, Wasserman et al found that germline TP53 mutations are common in children with adrenocortical carcinoma, with mutations encoding proteins with greater loss of function being at increased risk of multiple...
‘Frailty Profile’ Predicts Survival and Toxicities Among Elderly Patients With Multiple Myeloma
A frailty score predicts mortality and the risk of toxicity in elderly patients with multiple myeloma and can be used to determine more suitable therapies for these patients, the International Myeloma Working Group reported in Blood. “Chronologic age, performance status, and physician's...
Chemotherapy Trials for Advanced Cancers of the Lung and Pancreas Overestimate Survival for Elderly Medicare Patients
Results of clinical trials evaluating chemotherapy regimens for advanced pancreatic cancer and lung cancers “tended to correctly estimate survival for Medicare patients aged 65 to 74 years, but to overestimate survival for older Medicare patients by 6 to 8 weeks,” Lamont et al reported...
Use of Combined-Modality Therapy vs Chemotherapy Alone in Early Hodgkin Lymphoma Affected by Sex, Race, Distance to Treatment, and Insurance
In a study reported in the Journal of Clinical Oncology, Olszewski et al found that numerous factors affected use of combined-modality therapy vs chemotherapy alone in early-stage Hodgkin lymphoma, including sex, race, insurance, and distance to treatment facility. Study Details The study...
ASCO Expresses Concern Over the New CMS Oncology Care Model
On Thursday, February 12, 2015, the U.S. Department of Health and Human Services announced its new Oncology Care Model, a multipayer payment and care delivery model meant to support better health-care coordination for patients with cancer. Although commending the Centers for Medicare & Medicaid ...
FDA Approves Lenvatinib for Progressive Radioiodine-Refractory Differentiated Thyroid Cancer
The U.S. Food and Drug Administration (FDA) today granted approval to lenvatinib (Lenvima) to treat patients with progressive, differentiated thyroid cancer whose disease progressed despite receiving radioactive iodine therapy. Lenvatinib is a tyrosine kinase inhibitor that binds to multiple sites...
Sunitinib Active in Platinum-Refractory Thymic Carcinoma
In a phase II study reported in The Lancet Oncology, Thomas et al found that sunitinib (Sutent) was active in patients with platinum-refractory thymic carcinoma. Study Details In the open-label study, 23 evaluable patients with thymic carcinoma and 16 with thymoma who had disease progression...
Nutrient-Wide Association Study Shows Increased Coffee Intake May Be Associated With Lower Risk of Endometrial Cancer
Women who drank about four cups of coffee per day appeared to have decreased endometrial cancer risk compared with those who drank less than a cup each day, according to a study published by Merritt et al in Cancer Epidemiology, Biomarkers & Prevention. A New Approach “We used a...
Meaning-Centered Group Psychotherapy Improves Psychological Well-Being in Patients With Advanced Cancer
In a randomized trial reported in the Journal of Clinical Oncology, Breitbart et al found that meaning-centered group psychotherapy significantly improved psychological well-being compared with supportive group psychotherapy in patients with advanced or terminal cancer. Meaning-centered group...
Risk Assessment for Hodgkin Lymphoma Evolving, Promises Greater Precision and Specific Clinical Relevance
“Risk assessment in Hodgkin lymphoma is continuously evolving and promises even greater precision and specific clinical relevance in the future,” Joseph M. Connors, MD, stated in Blood. Dr. Connors is Clinical Professor, British Columbia Cancer Agency Centre for Lymphoid Cancer and the...
Scientists Identify Genetic Variations Linked to Treatment-Related Hearing Loss in Young Patients With Cancer
Using a genome-wide associated study approach, researchers have identified inherited genetic variations in the ACYP2 gene that were linked to as much as a fourfold greater risk of rapid hearing loss in young patients with newly diagnosed brain tumors treated with cisplatin chemotherapy. The study...
Study Identifies Eight Signs Associated With Impending Death in Cancer Patients
Researchers at The University of Texas MD Anderson Cancer Center have identified eight highly specific physical and cognitive signs associated with imminent death in cancer patients. The findings, published by Hui et al in Cancer, could offer clinicians the ability to better communicate with...
ASCO Endorses American Cancer Society Prostate Cancer Survivorship Care Guidelines
The American Society of Clinical Oncology (ASCO) has issued an endorsement of the American Cancer Society's (ACS) Prostate Cancer Survivorship Care Guidelines. These guidelines provide recommendations to primary care physicians on best practices in follow-up care for men after prostate cancer...
Reduced Use of Radiotherapy for Unresectable Pancreatic Adenocarcinoma in the United States
In a study reported in a research letter in JAMA Surgery, Shapiro et al found that use of radiotherapy in unresectable pancreas cancer has decreased over time and that disparities in use can be identified. Decreasing Use The study involved Surveillance, Epidemiology, and End Results (SEER) data...
Widespread Use of Docetaxel Preceded Phase III Evidence of Usefulness in Patients With Metastatic Prostate Cancer
Docetaxel was being widely used by patients with metastatic prostate cancer before phase III evidence that it was more effective than standard-of-care for patients with castration-resistant prostate cancer, according to an analysis of Medicare claims from before and after the trial results and...
Women Who Undergo Delayed Breast Reconstruction May Experience More Cancer‑Related Distress Than Women Who Undergo Mastectomy Alone
In women who have undergone mastectomy, those who underwent delayed breast reconstruction experienced greater cancer-related distress over the long term compared with women who underwent mastectomy alone, according to a prospective study by Metcalfe et al in the Journal of Surgical Oncology. For...
Study Shows Immunosuppressives, Chemotherapy May Reactivate Hepatitis B
Individuals previously infected with the hepatitis B virus (HBV) that receive chemotherapy or immunosuppressive treatment may be at risk of reactivating the virus, according to a report published by Di Bisceglie et al in Hepatology. Reactivation of HBV can be fatal, and researchers suggest routine...
Patients With Detectable PSA After Radical Prostatectomy May Benefit From More Aggressive Radiotherapy, 10-Year Post-Treatment Analysis Shows
Prostate cancer patients with detectable prostate-specific antigen (PSA) following radical prostatectomy should receive earlier, more aggressive radiotherapy, according to a study published by Wiegel et al in the International Journal of Radiation Oncology • Biology • Physics. German ARO ...
Analysis of Key Breast Cancer Genes Reveals Distinct Profiles for African American, European American Women
Researchers at Roswell Park Cancer Institute (RPCI) have uncovered new information that may begin to explain why many African American women are more likely to be diagnosed with aggressive, often deadly forms of breast cancer. Their findings also strengthen evidence that increased dietary folate...
Phase II Study Shows Activity of Everolimus and Letrozole in Recurrent Endometrial Carcinoma
Interaction of the estrogen receptor and PI3K/AKT/mTOR pathways and the finding of resistance to hormonal therapy mediated by PI3K activation suggest a benefit of adding an mTOR inhibitor to hormonal treatment in endometrial carcinoma. In a phase II study reported in the Journal of Clinical...
Immune Gene Profile Strongly Associated With Benefit of Adjuvant Trastuzumab in HER2-Positive Breast Cancer
In a study reported in the Journal of Clinical Oncology, Perez et al found that an immune function gene profile was associated with significantly improved relapse-free survival among patients with early-stage HER2-positive breast cancer who had trastuzumab (Herceptin) added to adjuvant chemotherapy ...
FDA Approves Palbociclib in Combination With Letrozole for Advanced Breast Cancer
The U.S. Food and Drug Administration has granted accelerated approval to palbociclib (Ibrance) in combination with letrozole for the treatment of postmenopausal women with estrogen receptor–positive, HER2-negative metastatic breast cancer who have not yet received an endocrine-based therapy. ...
Study Sheds New Light on Syndrome Associated With Aggressive Pediatric Cancer
A new study involving researchers at The University of Nottingham has revealed how children with an aggressive cancer predisposition syndrome experience a never-before- seen flood of mutations in their disease in very short periods of time. The findings were published by Shlien et al in Nature...
Dabrafenib May Stimulate Radioiodine Uptake in Patients With Iodine-Refractory Papillary Thyroid Cancer
In patients with iodine-refractory papillary thyroid cancer, the addition of dabrafenib (Tafinlar) therapy was shown to stimulate radioiodine uptake in thyroid cancer cells, according to a report by Rothenberg et al in Clinical Cancer Research. This approach has the potential advantage of requiring ...
ASCO Clinical Practice Guideline Update 2014: No Change to 2013 Venous Thromboembolism Prophylaxis and Treatment Guideline
As reported in the Journal of Clinical Oncology by Lyman et al, an ASCO update committee recommended no changes to the 2013 clinical practice guideline for venous thromboembolism (VTE) prophylaxis and treatment after review of 53 new publications in the area that became available between...
Study Finds Biologic Markers Associated With High-Risk Pancreatic Lesions
Pancreatic cancer affects approximately 46,000 people each year in the United States, and ranks fourth among the leading causes of cancer-related deaths. Only about 6% of individuals with pancreatic cancer will live 5 years after their diagnosis. One reason for this high mortality rate is the lack...
FDA Grants Breakthrough Therapy Designation to MPDL3280A for Non–Small Cell Lung Cancer
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Genentech’s investigational cancer immunotherapy MPDL3280A for the treatment of PD-L1–positive non–small cell lung cancer (NSCLC) that has progressed during or after platinum-based...
California Primary Care Physicians Struggle to Adapt to Breast Density Law, Study Shows
Ten months after California legislators enacted a controversial law mandating that radiologists notify women if they have dense breast tissue, University of California (UC), Davis researchers have found that half of primary care physicians are still unfamiliar with the law, and many don't feel...
Study Finds Metformin May Reduce Lung Cancer Risk Among Diabetic Nonsmokers
A large retrospective cohort study of diabetic patients taking metformin, a first-line treatment for type II diabetes, has found that while metformin use was not associated with lower lung cancer risk overall, the risk was 43% lower among diabetic patients who had never smoked. In addition, the...
High-Risk Prostate Cancer Detection More Likely With Targeted MRI/Ultrasound Fusion Technique Than With Standard Biopsy
Targeted biopsy using new fusion technology that combines magnetic resonance imaging (MRI) with ultrasound is more effective than standard biopsy in detecting high-risk prostate cancer, according to a study by Siddiqui et al published in JAMA. More than 1,000 men participated in the research at the ...
Protein-Based Therapy Shows Promise Against Resistant ALL in Preclinical Study
Chemotherapy resistance is one of the most formidable obstacles to treating acute lymphoblastic leukemia (ALL), the most common form of childhood cancer. Now researchers at Children’s Hospital Los Angeles (CHLA) have designed and developed a new protein-based therapy that may prove highly...
FDA Approves New Indication for Ibrutinib in Waldenström's Macroglobulinemia
The U.S. Food and Drug Administration (FDA) today expanded the approved use of ibrutinib (Imbruvica) for patients with Waldenström’s macroglobulinemia, a rare, indolent type of B-cell lymphoma. Ibrutinib is the first therapy indicated specifically for Waldenström’s...
No Benefit of High- vs Standard-Dose Radiotherapy or for Addition of Cetuximab to Chemoradiation in Stage IIIA or IIIB NSCLC
As reported in The Lancet Oncology by Bradley and colleagues, the phase III Radiation Therapy Oncology Group 0617 trial showed no survival benefit of high- vs standard-dose radiotherapy or for addition of cetuximab (Erbitux) to concurrent paclitaxel-carboplatin chemoradiation in patients with...
Study Uncovers Range of Molecular Alterations in Head and Neck Squamous Cell Carcinomas, New Potential Drug Targets
Investigators with The Cancer Genome Atlas (TCGA) Research Network have discovered genomic differences—with potentially important clinical implications—in human papillomavirus (HPV)-associated head and neck cancers. These findings were reported in Nature. The researchers also uncovered ...
Testosterone Therapy May Help Some Men With Castration-Resistant Prostate Cancer
According to researchers at the Johns Hopkins Kimmel Cancer Center, testosterone, which is generally thought to be a feeder of prostate cancer, has been found to suppress some advanced prostate cancers. The hormone may also reverse resistance to testosterone-blocking drugs used to treat prostate...
Study Finds Many Women Lack Understanding of Their Breast Cancer, Especially Minority Patients
A population-based study of women who had undergone surgery for breast cancer has found that many lacked understanding of the basic characteristics of their disease, including stage, grade, and tumor characteristics. Minority patients were less likely than white patients to have the correct...
Clonal Hematopoiesis With Somatic Mutations Increases With Age and Increases Risk of Hematologic Cancer and Mortality
In a study reported in The New England Journal of Medicine, Genovese et al found that clonal hematopoiesis with somatic mutations is increasingly common with greater age and is associated with increased risk of hematologic cancer. The presence of such clonal hematopoiesis in apparently healthy...
Analysis of Unexplored Part of Human Genome May Lead to Cancer Biomarker Development
A new analysis opens the door to the discovery of thousands of potential new cancer biomarkers, according to a recent study by Iyer et al published in Nature Genetics. Long Noncoding RNA Researchers at the University of Michigan Comprehensive Cancer Center analyzed the global landscape of long...
RTOG 9910 Trial Shows No Benefit of Longer Androgen Suppression Before Radiotherapy for Localized Prostate Cancer
As reported by Pisansky et al in the Journal of Clinical Oncology, the Radiation Therapy Oncology Group (RTOG) 9910 trial showed no benefit of extending the duration of pre–radiation therapy androgen suppression on survival or disease control among patients with localized prostate cancer....
Researchers Identify Potential Treatment Targeting Proliferation Pathway in Some Aggressive Tumors
Researchers from the Massachusetts General Hospital (MGH) Cancer Center and Boston University School of Medicine (BUSM) have identified a potential treatment targeting a pathway by which several aggressive tumors maintain their ability to proliferate, according to a study by Flynn et al published...
Long-Term Use of Hormonal Contraceptives Could Lead to Increased Risk of Brain Tumors
Taking a hormonal contraceptive for at least 5 years is associated with a possible increase in women’s risk of developing a glioma, according to a study by Andersen et al published in the British Journal of Clinical Pharmacology. Study Details While little is known about the causes of...
No Survival Benefit of Adding Erlotinib to Sorafenib in Advanced Hepatocelluar Carcinoma
In the phase III SEARCH trial reported in the Journal of Clinical Oncology, Zhu et al found no overall survival benefit of adding erlotinib (Tarceva) to sorafenib (Nexavar) in patients with advanced hepatocellular carcinoma. Study Details In this double-blind trial conducted in 26 countries in...
TP53 Mutations May Play a Role in Treatment‑Related Acute Myeloid Leukemia and Myelodysplastic Syndrome
A genomic study of cancer patients previously treated with chemotherapy or radiation therapy found that TP53 mutations may play a role in the development of treatment-related acute myeloid leukemia (AML) and myelodysplastic syndrome, according to a report by Wong et al in Nature. However, the...
ATRX Mutation Linked to Brain and Pancreatic Neuroendocrine Tumors May Be Biomarker for Rare Adrenal Tumors
A somatic mutation in the ATRX gene has recently been identified as a potential molecular marker for gliomas, neuroblastomas, and pancreatic neuroendocrine tumors. Now, researchers at the Perelman School of Medicine at the University of Pennsylvania have found that the same mutated gene may serve...
